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Abstract We study the production of radioisotopes
for nuclear medicine in (γ, xn + yp) photonuclear re-
actions or (γ, γ′) photoexcitation reactions with high
flux [(1013 − 1015)γ/s], small diameter ∼ (100µm)2 and
small band width (∆E/E ≈ 10−3− 10−4) γ beams pro-
duced by Compton back-scattering of laser light from
relativistic brilliant electron beams. We compare them
to (ion,xn+yp) reactions with (ion=p,d,α) from particle
accelerators like cyclotrons and (n,γ) or (n,f) reactions
from nuclear reactors. For photonuclear reactions with
a narrow γ beam the energy deposition in the target
can be managed by using a stack of thin target foils or
wires, hence avoiding direct stopping of the Compton
and pair electrons (positrons). However, for ions with a
strong atomic stopping only a fraction of less than 10−2
leads to nuclear reactions resulting in a target heating,
which is at least 105 times larger per produced radioac-
tive ion and is often limits the achievable activity. In
photonuclear reactions the well defined initial excitation
energy of the compound nucleus leads to a small num-
ber of reaction channels and enables new combinations of
target isotope and final radioisotope. The narrow band-
width γ excitation may make use of the fine structure
of the Pygmy Dipole Resonance (PDR) or fluctuations
in γ-width leading to increased cross sections. Within
a rather short period compared to the isotopic half-life,
a target area of the order of (100µm)2 can be highly
transmuted, resulting in a very high specific activity.
(γ, γ′) isomer production via specially selected γ cas-
cades allows to produce high specific activity in multi-
ple excitations, where no back-pumping of the isomer
to the ground state occurs. We discuss in detail many
specific radioisotopes for diagnostics and therapy ap-
plications. Photonuclear reactions with γ beams allow
to produce certain radioisotopes, e.g. 47Sc, 44Ti, 67Cu,
103Pd, 117mSn, 169Er, 195mPt or 225Ac, with higher spe-
cific activity and/or more economically than with clas-
sical methods. This will open the way for completely
Send offprint requests to:
new clinical applications of radioisotopes. For example
195mPt could be used to verify the patient’s response to
chemotherapy with platinum compounds before a com-
plete treatment is performed. Also innovative isotopes
like 47Sc, 67Cu and 225Ac could be produced for the first
time in sufficient quantities for large-scale application in
targeted radionuclide therapy.
1 Introduction
In nuclear medicine radioisotopes are used for diagnos-
tic and therapeutic purposes [1,2]. Many diagnostics ap-
plications are based on molecular imaging methods, i.e.
either on positron emitters for 3D imaging with PET
(positron emission tomography) or gamma ray emitters
for 2D imaging with planar gamma cameras or 3D imag-
ing with SPECT (single photon emission computer to-
mography)1. The main advantage of nuclear medicine
methods is the high sensitivity of the detection systems
that allows using tracers at extremely low concentrations
(some pmol in total, injected in typical concentrations of
nmol/l). This extremely low amount of radiotracers as-
sures that they do not show any (bio-)chemical effect
on the organism. Thus, the diagnostic procedure does
1 Today the nuclear medicine imaging techniques PET and
SPECT (using radionuclides injected into the patient’s body)
are frequently combined in the same apparatus with the radi-
ology technique CT (computer tomography) to PET/CT or
SPECT/CT, respectively. CT is based on transmission ra-
diography with X-rays and provides structural information
to better localize the features observed on PET or SPECT
images. CT information helps also to perform the attenuation
correction. However, the combination with CT, or not, does
not affect the choice of the PET or SPECT tracer isotopes
which is the main issue in the present discussion. Hence we
use PET and SPECT, which implicitly includes CT where
adequate.
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not interfere with the normal body functions and pro-
vides direct information on the normal body function,
not perturbed by the detection method. Moreover, even
elements that would be chemically toxic in much higher
concentrations can be safely used as radiotracers (e.g.
thallium, arsenic, etc.). To maintain these intrinsic ad-
vantages of nuclear medicine diagnostics one has to as-
sure that radiotracers of relatively high specific activity
are used, i.e. that the injected radiotracer is not accom-
panied by too much stable isotopes of the same (or a
chemically similar) element.
Radioisotopes are also used for therapeutic appli-
cations, in particular for endo-radiotherapy. Targeted
systemic therapies allow fighting diseases that are non-
localized, e.g. leukemia and other cancer types in an
advanced state, when already multiple metastases have
been created. Usually a bioconjugate [1] is used that
shows a high affinity and selectivity to bind to peptide
receptors or antigens that are overexpressed on certain
cancer cells with respect to normal cells. Combining such
a bioconjugate with a suitable radioisotope such as a
(low-energy) electron or alpha emitter, allows irradiat-
ing and destroying selectively the cancer cells. Depend-
ing on the nature of the bioconjugate, these therapies
are called Peptide Receptor Radio Therapy (PRRT) [2,
3] when peptides are used as bioconjugates or radioim-
munotherapy (RIT) [2,?], when antibodies are used as
bioconjugates. Bioconjugates could also be antibody-
fragments, nanoparticles, microparticles, etc. For cancer
cells having only a limited number of selective binding
sites, an increase of the concentration of the bioconju-
gates may lead to blocking of these sites and, hence, to a
reduction in selectivity. Therefore the radioisotopes for
labeling of the bioconjugates should have a high specific
activity to minimize injection of bioconjugates labeled
with stable isotopes that do not show radiotherapeutic
efficiency. Thus often high specific activities are required
for radioisotopes used in such therapies.
The tumor uptake of bioconjugates varies consid-
erably from one patient to another. This leads to an
important variation in dose delivered to the tumor if
the same activity (or activity per body mass or activ-
ity per body surface) was administered. Ideally a per-
sonalized dosimetry should be performed by first inject-
ing a small quantity of the bioconjugate in question,
marked by an imaging isotope (preferentially β+ emit-
ter for PET). Thus the tumor uptake can be quantita-
tively determined and the injected activity of the ther-
apy isotope can be adapted accordingly. To assure a rep-
resentative in-vivo behaviour of the imaging agent, the
PET tracer should be ideally an isotope of the same ele-
ment as the therapy isotope, or, at least of a chemically
very similar element such as neighboring lanthanides.
Thus so-called “matched pairs” of diagnostic and ther-
apy isotopes are of particular interest: 44Sc/47Sc, 61Cu
or 64Cu/67Cu, 86Y/90Y, 123I or 124I/131I or 152Tb/149Tb
or 161Tb. Often the production of one of these isotopes
is less straightforward with classical methods. There-
fore “matched pairs” are not yet established as standard
in clinical practice. The “matched pairs” of scandium
and copper can be produced much better with γ beams.
Valence-III elements do not necessarily show an identical
in-vivo behaviour [5,6] but in many cases they are suffi-
ciently similar. For example the 68 min PET tracer 68Ga
is conveniently eluted from 68Ge generators and used as
imaging analog for the therapy isotopes 90Y, 177Lu or
213Bi [7].
The radioisotopes for diagnostic or therapeutic nu-
clear medicine applications are usually produced by nu-
clear reactions. The required projectiles are typically
either neutrons (from dedicated irradiation reactors)
or charged particles (from small or medium-sized cy-
clotrons or other accelerators). In section 2 we shortly
discuss these presently used techniques and then intro-
duce in section 3 the new γ beams with high γ energies,
high intensities and small bandwidth. Such a γ facility
will typically consist of an electron linac, delivering a
relativistic electron beam with high brilliance and high
intensity from which intense laser beams are Compton
back-scattered. These γ facilities allow to produce many
radioisotopes in new photonuclear reactions with signif-
icantly higher specific activity. In section 4 we compare
for certain radioisotopes of interest the specific activi-
ties achievable with presently used production reactions
and γ-beams respectively. In section 5 the energy deposi-
tion of γ beams is compared to ion beams, showing that
targets can endure higher intensities of γ beams than
ion beams allowing for higher γ flux densities. We will
discuss interesting cases of specific radioisotopes in sec-
tion 6. Besides attaching radiosiotopes to biomolecules
in therapeutical applications, we discuss in section 7 new
ways of brachytherapy. Finally in section 8 the advan-
tages of producing radioisotopes by γ beams are out-
lined.
2 Presently used Nuclear Reactions to Produce
Medical Radioisotopes
Today the most frequently employed nuclear reactions
for the production of medical radioisotopes are:
1 Neutron capture
Neutron capture (n,γ) reactions transmute a stable
isotope into a radioactive isotope of the same ele-
ment. High specific activities are obtained, when the
(n,γ) cross section is high and the target is irradi-
ated in a high neutron flux. Neutrons most useful for
(n,γ) reactions have energies from meV to keV (ther-
mal and epithermal neutrons) and are provided in the
irradiation positions of high flux reactors at flux den-
sities of 1014 n/(cm2s) up to few 1015 n/(cm2s). If the
neutron capture cross section is sufficiently high (e.g.
2100 barn for 176Lu(n,γ)177Lu), then a good fraction
of the target atoms can be transmuted to the desired
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product isotopes, resulting in a product of high spe-
cific activity.
Note that the specific activity of the product depends
on the neutron flux density (n/(cm2s)) and not on
the total number of neutrons provided by the reac-
tor. Hence irradiation reactors are optimized to pro-
vide a high flux density in a limited volume, while
keeping the total neutron rate (that is proportional
to the thermal power) relatively low. This optimiza-
tion is inverse to a power reactor that should provide
a high thermal power at limited neutron flux density
(to limit the power density, damage to structural ma-
terials and extend the operation time between refu-
elling).
High specific activities can also be achieved by using
indirect production paths. The (n,γ) reaction is not
populating directly the final product but a precur-
sor that decays by beta decay to the final product.
Thus the final product differs in its chemical proper-
ties from the target and can be chemically separated
from the bulk of the remaining target material. This
method is e.g. used to produce 177Lu in non-carrier
added quality by irradiating enriched 176Yb targets
in a high neutron flux to produce 177Yb that subse-
quently decays to 177Lu. The latter is extracted by a
chemical Lu/Yb separation.
2 Nuclear fission
Fission is another process used for isotope produc-
tion in nuclear reactors. Radiochemical separation
leads to radioisotopes of “non-carrier-added” quality,
with specific activity close to the theoretical maxi-
mum. Fission is the dominant production route for
the generator isotopes 99Mo and 90Sr, for the β−
emitting therapy isotope 131I and for the SPECT iso-
tope 133Xe.
3 Charged particle reactions with p, d or α ions
Imaging for diagnostic purposes requires either β+
emitters for PET (mainly 18F, 11C, 13N, 15O, 124I or
64Cu), or isotopes emitting gamma-rays with suitable
energy for SPECT (about 70 to 300 keV), if pos-
sible without β+/− emission to minimize the dose
to the patient. Thus electron capture decay is pre-
ferred for such applications, e.g.: 67Ga, 111In, 123I,
201Tl. Usually these neutron-deficient isotopes can-
not be produced by neutron capture on a stable iso-
tope (exception 64Cu). Instead they are mainly pro-
duced by charged-particle induced reactions such as
(p,n), (p,2n),. . . High specific activities of the final
product are achievable, when the product differs in
chemical properties from the target (i.e. different Z)
and can be chemically separated from the remaining
bulk of target material2. Thus Z must be changed in
the nuclear reaction, e.g. in (p,n), (p,2n), (p,α) reac-
2 Note that in principle very high specific activities may be
achieved in this way. However, the effective specific activities
that measure the ratio between wanted radioisotopes to all
elements (mostly metals) that may affect, e.g., the labeling of
tions. The energies of the charged particle beams for
such reactions are usually in the range of 10 to 30
MeV and can be supplied with high currents (0.1 to
1 mA) by small cyclotrons.
Table 1 Radioisotopes for nuclear medicine produced in
generators. ∗: 212Pb and 213Bi are the grand-grand-daughters
and 212Bi is the grand-grand-grand-daughter of the respec-
tive generator isotope.
mother isotope T1/2 daughter isotope T1/2
44Ti 60.4 a 44Sc 3.9 h
52Fe 8.3 h 52Mn 21 m
68Ge 288 d 68Ga 68 m
81Rb 4.6 h 81Kr 13 s
82Sr 25.0 d 82Rb 76 s
90Sr 28.5 a 90Y 64 h
99Mo 66 h 99mTc 6.0 h
188W 69 d 188Re 17 h
224Ra 3.7 d 212Pb∗ 10.6 h
224Ra 3.7 d 212Bi∗ 61 m
225Ac 10 d 213Bi∗ 45 m
4 Generators
Another important technique is the use of genera-
tors, where short-lived radionuclides are extracted
“on-tap” from longer-lived mother nuclides. Here the
primary radioisotope (that was produced in the nu-
clear reaction) has a longer half-life than the final
radioisotope (that is populated by decay of the pri-
mary radioisotope and is used in the medical appli-
cation). The primary radioisotope is loaded onto the
generator and stays there chemically fixed. The final
radioisotope will grow in, populated by the decay
of the primary radioisotope. It can be repetitively
eluted and used. For the extraction of the shorter-
lived isotope chromatographic techniques, distilla-
tion or phase partitioning are used. Depending on
the generator technology, there is usually a limit to
which a generator can be loaded with atoms of the
primary product element (e.g. molybdenum on acid
alumina columns). If more is loaded, then a signif-
icant part of the primary product isotope might be
eluted too (“breakthrough”), leading to an inaccept-
able contamination of the product with long-lived
activity. To prevent such problems, generators are
generally loaded with material of a given minimum
specific activity.
5 Photonuclear reactions
The inverse process to (n,γ), namely (γ,n), also al-
bioconjugates, might be significantly lower since stable ele-
ments can be introduced due to the finite purity of chemicals,
columns, etc. used in the chemical processing. Such problems
are generally reduced when higher activities per batch are
processed.
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as a function of time.
lows producing neutron deficient isotopes, but con-
ventional γ ray sources do not provide sufficient flux
density for efficient production of radioisotopes with
high total activity and high specific activity. There-
fore this process plays no role in present radioisotope
supply.
3 γ Beams
The new concept of isotope production with a γ beam
only became possible, because very brilliant γ sources
are being developed, where the γ rays are produced by
incoherent Compton back-scattering of laser light from
brilliant high-energy electron bunches. Fig. 1 and Fig. 2
show the rapid progress of γ beam properties for the
bandwidth (Fig. 1) and the peak brilliance (Fig. 2) with
time, starting with the bremsstahlung spectrum of the
Stuttgart Dynamitron [8], which still had a very large
bandwidth.
For Compton back-scattering in a head-on collision
the γ energy is given by:
Eγ =
4γ2eEL
1 + (γeΘγ)2 + 4γeEL/mc2
(1)
with the γe factor, characterizing the energy of the
electron beam, the γ energy Eγ , its angle Θγ and the
laser photon energy EL. The energy Eγ decreases with
Θγ . A small bandwidth of the γ beam requires a small
energy spread of the electron bunches (∆γe/γe), a small
bandwidth of the laser energy (∆EL/EL) , a very good
emittance of the electron beam with a small opening
angle and small opening angle of the laser beam. At
the HIγS facility (Duke University, USA) the photons
are produced by a Free Electron Laser (FEL) and then
are back-scattered from a circulating electon beam [9].
This facility already produced high energy γ rays (1-100
MeV), but the flux (105 − 5 · 108γ/s) was too weak for
radioisotope production. C. Barty and his group at the
Lawrence Livermore National Laboratory (LLNL) devel-
oped already three generations of incoherent Compton
back-scattering sources: PLEIADES [10], T-REX [11]
and MEGa-Ray [12], each based on a “warm” electron
linac and a fibre laser for back-scattering. Recently the
electron linac technology was switched from S-band tech-
nology (4 GHz) for T-REX to X-band technology (12
GHz) for MEGa-Ray. Here electron bunches with 250
PC are used. The MEGa-Ray γ beam runs with a macro-
pulse structure of 120 Hz using 1.5 J, 2 ps laser pulses,
which are recirculated 100 times with 2 ns bunch spacing
in a ring-down cavity. The group plans for lower energy
γ rays in the range of a only few MeV, too small for pho-
tonuclear reactions. A similar γ facility is planned for the
ELI-Nuclear Physics project (ELI-NP) in Romania [13],
also based on a “warm” linac like the one used at MEGa-
Ray, however designed for γ energies up to 19 MeV, thus
reaching interesting intensities and γ energies for isotope
production. R. Hajima and coworkers at Ibaraki (Japan)
are developping a Compton back-scattering γ beam us-
ing an energy recovery linac (ERL) and superconducting
“cold” cavities [14]. For smaller electron bunch charges
(8 pC) very low normalized emittances of 0.1 mm mrad
can be obtained from the electron gun. For the reflected
laser light a high finesse enhancement cavity is used for
recirculating the photons. The quality of the electron
beam from the ERL can be preserved by running with
higher repetition rate (GHz). Switching from a 1 mA
electron current to a 100 mA current the peak brilliance
and bandwidth can be improved significantly [15,16]. In-
tensities of 5 · 1015γ/s are expected [15].
Also laser-accelerated electron bunches have been
proposed as relativistic mirrors for Compton back-
scattering and the production of intense γ beams [17].
The yield of resonant photonuclear reactions (dis-
cussed below) depends strongly on the exact energy and
the bandwidth of the gamma beam. Both parameters are
determined by the quality of the laser beam and of the
electron beam respectively. The laser beam parameters
are usually well controlled by conventional means used in
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laser spectroscopy. More importantly, the electron beam
parameters need to be tuned and monitored with good
precision. For a meaningful monitoring system the γ ray
energy has to be measured with a system that has (far)
better energy resolution than the γ beam itself. It is not
trivial to measure high energy gamma ray energies with
such high precision. For gamma rays in the MeV range
usual Ge detectors are limited to an energy resolution of
the order of 10−3. Scintillation detectors have an even
worse energy resolution. Hence, more complex and “un-
usual” methods have to be used for this purpose. The
two methods are shown schematically in Fig. 3, where
an energy recovery linac can supply many γ beams.
Two methods are preferable:
A crystal spectrometer A thin single or mosaic crystal
(e.g. Si, Ge, SiO2, Cu, graphite, etc.) is placed in
the gamma beam (in front, inside or behind a pro-
duction target). A small fraction of the beam will
be diffracted by the crystal according to the Bragg
condition:
2d sin θ = nλ (2)
d is the well-known crystal lattice spacing, n is the re-
flection order, λ is the wavelength of the γ beam and
θ is the diffraction angle. Placing a γ ray detection
system at large distance allows measuring the diffrac-
tion angle θ, either by scanning the beam through
narrow collimators by turning the crystal or by us-
ing a fixed crystal and a detector with good position
resolution. Hence. the wavelength of the γ rays is
deduced which gives directly the γ ray energy. The
angular spread of the diffracted beam is a measure of
the energy spread of the γ beam. These data can be
used for a feedback system for tuning and monitoring
the electron beam for the γ beam production. Due
to the high intensity of the γ beam, even with thin
crystals and in high reflection order enough photons
will arrive at the detector. A higher reflection order
is preferred since it allows placing the detector fur-
ther away from the direct non-diffracted beam. For γ
beams of larger opening angle, the latter would limit
the achievable energy resolution. Here it is preferable
to use two consecutive crystals for diffraction: a first
one placed in the γ beam to diffract out a small frac-
tion. The small intrinsic angular acceptance of the
crystal will effectively act as collimator. The second
crystal receives therefore a well-collimated beam. Ad-
ditional collimators can be placed between both crys-
tals and/or between the second crystal and the detec-
tor respectively to eliminate background from other
diffraction orders. Using two consecutive diffractions
in the same direction will add to the energy disper-
sion and provide very high energy resolution, two
diffractions in opposite direction allows measuring
the intrinsic resolution of the measurement system.
The rotation angle of the crystals is usually con-
trolled by laser interferometers. Such a double crystal
spectrometer enables measuring γ ray energies with
a resolution below 10−6 [18], i.e. covering fully the
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needs to stabilize the γ beam in a bandwidth of 10−5
to 10−3.
B (γ,n) threshold reaction with neutron time-of-flight spectrometer
Alternatively to a crystal spectrometer also a second
γ beam from a second γ ray production station
(possibly using a different laser wavelength) can be
used for monitoring the electron beam energy. This
second γ beam is sent on a dedicated target where
it induces (γ,n) reactions just above the threshold
and neutrons are released in the eV to keV range.
Due to the pulsed nature of the γ beam, the neutron
energy can be measured by time-of-flight with good
precision (few eV or better). Adding the measured
neutron energy to the well-known neutron binding
energy of the target provides an accurate on-line
measurement (order of 10−6 resolution) of the γ
beam energy and γ beam energy spread, hence also
of the electron beam energy and electron beam
energy spread. Again this information is used for
a feedback system to optimize and stabilize the
electron accelerator parameters. Neutron detection
can be realized in various way. One possibility is the
use of a “neutron converter” (containing isotopes
like 6Li, 10B or 235U) combined with a charged
particle detector. Using a segmented detector ar-
ray many neutrons could be measured per bunch
allowing for a fast feedback system. The length of
the neutron flight path should be adjusted to the
neutron energies.
4 Specific Activity of Radioisotopes and
Photonuclear Cross Sections
One of the most important quality criteria for radioiso-
topes for nuclear medicine applications is the specific
activity (A/m), usually expressed in GBq/mg, Ci/mg or
similar units. The theoretical maximum specific activ-
ity for a pure radioisotope without admixture of stable
isotopes is given by:
(
A
m
)
max
=
ln(2)
T1/2
·NA
M
(3)
Where T1/2 is the half-life of the radioactive isotope,
M is the molar mass (g/mol) of the target isotope and
NA = 6.02 · 1023 denotes Avogadro’s constant.
For example an isotope with M = 100 g/mol and
T1/2 = 7 days would have a theoretical specific activity
of nearly 7 TBq/mg.
If other reactions (such as destruction of the product
by nuclear reactions) do not interfere significantly, then
the achievable specific activity is given by:
A
m
=
NA
M
σ · Φ ·
[
1− exp(− ln(2)tirr/T1/2
)
] (4)
Where:
M the molar mass of the target isotope
σ the cross-section for transmutation of the
target into the product
Φ the particle flux density
tirr the irradiation time
T1/2 the half-life of the product isotope
After sufficiently long irradiation (multiple of prod-
uct half-life) the specific activity approaches saturation:
A
m
=
NA
M
σ · Φ (5)
Comparison of equations 3 and 5 shows that the
necessary condition to reach high specific activities is:
σ · Φ ≈ ln(2)/T1/2
Radioisotopes for medical applications have typically
half-lives of hours to days, hence the flux density (in
part./(cm2s)) should approach or exceed a value of about
1019/σ (in barn). For future planned γ beams with
5 · 1015γ/s over areas of (0.1 mm)2 the flux density can
reach several 1019γ/(cm2 s), i.e. the target can be effi-
ciently transmuted by photonuclear reactions with few
100 mb cross-section. For resonant reactions with higher
cross-sections even the flux densities of the less powerful
γ beam facilities (1017γ/(cm2 s)) will assure a relatively
high specific activity of the product.
The specific activity of a radioisotope product in
units of GBq/mg or Ci/mg is a measure of quality famil-
iar to the users in nuclear medicine. However, the the-
oretical specific activity varies with the half-life. Hence
a tabulation of different isotopes and their achievable
specific activities is less comprehensible. Therefore we
define in addition the ratio R =[(A/m)/(A/m)max] that
indicates how close the specific activity comes to the the-
oretical optimum. For R = 0.5 one radioactive atom will
be accompanied by one stable atom (of the same element
or target, respectively), for R = 0.1 only one out of ten
atoms is the radioisotope of interest, etc.
We will compare R(n,γ)=[(A/m)/(A/m)max](n,γ) for
classical production in (n,γ) reactions to
Rγ= [(A/m)/(A/m)max]γ for γ-beams.
The finally reached specific activity is also deter-
mined by the undesired further transmutation (burnup)
of the wanted reaction product. This product burnup be-
comes significant when the product fraction gets high.
For (n,γ) reactions in high flux reactors it may even-
tually limit the achievable specific activity if the neu-
tron capture cross-section of the product is high. For
153Gd, 159Dy, 169Yb or 195mPt this seriously limits the
achievable specific activity. For photonuclear reactions
the cross sections for product creation and destruction
are comparable in case of (γ,n) reactions, while for (γ,p)
and (γ,2n) reactions the destruction cross-section may
be up to one order of magnitude larger. This limits the
ultimately achievable specific activity to R ≈ 0.5 in the
first case and to R ≈ 0.1 in the latter cases. Product
burnup becomes noticeable when approaching these lim-
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its. If the cross-sections were known, the effect could be
calculated precisely by the Bateman equations.
In some cases a secondary product produced by a re-
action on the primary desired product may present a dis-
turbing radionuclide impurity. For example when 125I is
produced by 124Xe(n,γ)125Xe(β−), then the irradiation
should be kept short enough to minimize production of
disturbing 126I by 125I(n,γ) reactions.
If one looks at measured photonuclear cross-sections
one typically finds cross sections below 1 barn. As a pro-
totype we show in Fig. 4 the photonuclear cross-sections
for 160Gd. The arrows with separation energies indicate
the thresholds for the (γ, xn+yp) reactions. Close to
threshold a transmission factor of the neutron and the
proton reduces the cross-section. The protons in addi-
tion have a reduction by a Coulomb tunneling factor
exp
(
−pi(Z−1)e
2
h¯v
)
with the velocity v of the proton and
the charge Z of the nucleus, where Coulomb hindrance
prevails up to the Coulomb energy Ec =
(Z−1)2e2
R with
the nuclear radius R. The exponential rise of the start-
ing (γ, xn) reaction cross-sections is due to the increase
in compound nucleus resonance level density.
If we could look with higher resolution into the pho-
tonuclear cross-sections, we would observe individual
resonances characterized by a width Γ . The cross-section
for a compound nucleus resonance of the (γ,x) reaction
at the resonance energy Er is given by the Breit-Wigner
formula [20]:
σ(Eγ) = (λ
2
γ/4pi) · g ·
ΓγΓd
(Eγ − Er)2 + (Γ )2/4
(6)
g is a spin factor close to unity. λγ = h¯/(Eγ · c)
represents the wavelength of the γ rays with energy Eγ .
Γ is the total width of the resonance with Γ = Γγ+Γd+
ΓD and the decay widths Γd to the desired product and
ΓD to all other exit channels. ΓD may become important
for less favored reactions like (γ,p).
The width Γγ has been studied systematically as a
function of A at the neutron separation energy [20] and
we obtain an average Γγ ≈ 100 meV for nuclei with
A = 160. Frequently the integrated cross-section, i.e.
the product of cross-section times the width Γ is given,
which in our case is about 2 b·eV.
The energy spacing of the compound nuclear reso-
nances for a given spin and parity at the neutron binding
energy for A = 160 is about D ≈ 10 eV [20]. It can be
calculated from the back-shifted Fermi-gas formula [21].
Thus with Γ/D ≈ 1% probability we hit a resonance. In
Fig. 5 we show these Breit-Wigner resonances.
For a given γ beam energy of 7 MeV, a bandwidth
∆E ≈ 7 keV will cover about 700 resonances. The width
Γγ , where we have shown the average in Fig. 4, has a
Porter-Thomas distribution [22,23]
P (s) =
1√
2pis
· exp(−s/2). (7)
with s = Γγ/ < Γγ >. So most of the resonances
have a very small γ width and very few levels show a
much larger width. Thus from energy bin to energy bin
we expect large fluctuations of the average value within
the bin and we can select an energy bin with a large
cross section. The smaller the bandwidth of the γ-beam,
the larger these fluctuations become and one may select
e.g. bins with 10 times larger average cross section. Since
the level spacings D grow exponentially when reducing
the mass number A at the same excitation energy, these
fluctuations become more pronounced for lighter nuclei.
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Fig. 5 Breit-Wigner cross sections (red), Breit-Wigner cross
section broadened by the Doppler effect (green) and the en-
ergy averaged cross sections ( dashed blue), showing the much
larger individual resonance cross sections.
The Doppler broadening of a γ transition at room
temperature kT = 1/40 eV for a nucleus with mass num-
ber A = 160 and a γ energy Eγ= 7 MeV is
∆Eγ = Eγ
√
(2kT )/muc2A ≈ 4 eV (8)
Thus the line is broadened with respect to the natural
linewidth by a factor of ≈ 40.
Here the spectral flux density Φ/(∆E) is an
important quantity, where we will reach val-
ues of 1013γ/(cm2·s·eV) at ELI-NP, but up to
1017γ/(cm2·s·eV) in Compton back-scattering with
energy recovery electron linacs. The specific activity at
saturation can then be calculated by multiplying the
integrated cross-section σ(Er) · Γ with the probability
to hit a resonance and the spectral flux density:
A
m
=
NA
M
[σ(Er) · Γ ]
Γ
D
·
(
Φ
∆E
)
(9)
5 Comparison of the Energy Loss in the Target
between Photonuclear and Ion-induced
Reactions
Gamma rays deposit their energy in quantized interac-
tions with matter, such as Compton scattering, pair cre-
ation, photo effect or photonuclear reactions. For photon
energies between 10 and 30 MeV, the total cross-section
is dominated by Compton scattering and pair production
in the nuclear field. The dependence of the cross sections
as a function of γ energy and target element is given in
Ref. [24]. The Compton cross-section rises proportion-
ally to the number of electrons per atom, i.e. to Z, while
the cross-section for pair production rises roughly with
Z2. At 15 MeV γ energy we find for carbon a total cross
section of 0.34 b/atom, while for lead this value amounts
to 20 b/atom. Generally the cross section is rather flat in
this energy region. While for carbon the Compton cross-
section is twice the pair creation cross section, for lead
the pair creation is five times more important than the
Compton effect.
For 10 MeV γ quanta the angle of the Compton scat-
tered γ’s is confined to about 10 degrees and the cross-
section is strongly peaked in forward direction with an
energy loss of less than 300 keV. If we assume a typical
total cross-section of 10 b/atom and a target thickness
of 106 atomic layers, about 5% of the γ quanta will suf-
fer an energy loss by Compton scattering of 100 keV and
about 5% will undergo pair creation at 10 MeV. How-
ever, in such thin targets of less than 0.1 g/cm2 less than
10−2 of the electrons are stopped and less than 5 · 10−5
of the energy is deposited.
In contrast to gamma rays, charged particles deposit
their energy continuously while being slowed down in
matter. The mean rate of energy loss is given in units
of (MeV/(g/cm2)) (stopping power) by the Bethe-Bloch
equation:
− dE
dx
= Kz2
Z
A
1
β2
[
1
2
ln
2mec
2β2γ2Tmax
I2
− β2 − δ
2
]
(10)
with K=4piNAr
2
emec
2=0.307 MeV cm2. Here Tmax is
the maximum kinetic energy, which can be transfered in
a single collision, Z the atomic number of the target, A
the atomic number of the target, ze the charge of the ion
and δ a density effect correction to the ionization energy
loss. For 10 MeV protons we obtain 30 MeV/(g/cm2).
Therefore with the density of iron of 7.9 g/cm3 we have
an energy loss of 10 MeV in 0.26 mm. In these 2.6 · 106
atomic layers at A˚ distances, about 10−8 reactions occur
per atomic layer or 2.6% in total. Thus we deposit per
produced new radioactive nucleus about 400 MeV. The
energy deposition is about a factor of 105 larger for pro-
tons compared to γ’s for the same number of produced
nuclei.
The typical intensity of proton beams used for iso-
tope production is of the order of 100 µA/cm2, corre-
sponding to 6 · 1014/(cm2s). On the other hand, the
target should withstand a higher γ flux density of
1019/(cm2s). However, for Bremsstrahlung beams one
has a strong rise of the γ ray spectrum to low energies
with increased energy deposition at lower energies, mak-
ing it worse compared to proton activation.
6 Specific Radioisotopes produced in
Photonuclear Reactions
We now discuss in detail the different γ-induced reac-
tions and specific radioisotopes that can be produced by
such reactions.
In tables 2 and 3 we show estimates of the achievable
specific activities for thin targets for a γ flux of 1014
per s, corresponding to a flux density of 1018 γ/(cm2
s). With a bandwidth of 10−3 this results at 10 MeV
in a spectral flux density of 1014 γ/(cm2 s eV). These
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values are inbetween the characteristics of presently built
facilties (e.g. MEGa-RAY) and future improved facilities
(100 mA ERL). We compare these to thin target yields
obtained by thermal neutron capture in a typical flux
density of 1014 n/(cm2 s) in high flux reactors. Note
that alike for the potential beam parameters of γ beam
facilities, there is also a wide range for the flux density
really available at the irradiation positions of high flux
reactors. Some positions provide flux densities of several
1012 to 1013 n/(cm2 s), while few special reactors have
positions that even exceed 1015 n/(cm2 s), namely SM3
in Dimitrovgrad [25], HFIR in Oak Ridge [26] and ILL’s
high flux reactor in Grenoble.
Since hitherto no γ beams with sufficiently small
bandwidth were available to exploit resonant excitation,
there are obviously no such measured cross-sections.
Hence, we can only estimate a lower bound using the
averaged cross-sections measured at Bremsstrahlung fa-
cilities [19,27,29,28,30]. For cases where no measured
cross-sections are available, we interpolate experimental
cross-sections of the same reaction channel on nearby
elements, taking into account the energy above the re-
action threshold.
Even when using these conservative assumptions, the
estimated specific activities are very promising for spe-
cific isotopes.
The total activity in a nuclear reactor can be rela-
tively high since thick (several cm) and large (several
cm2) targets can be used if the cross-sections are not
too high (leading to self absorption and local flux de-
pression). Multiple irradiation positions allow producing
various radioisotopes with activities of many TBq.
For the γ beam we estimate the total activities by in-
tegrating to one interaction length, i.e. where the initial
γ-beam intensity has dropped to 1/e = 37 % of its inten-
sity. Higher total activities can be achieved with thicker
targets at the expense of lower specific activity and vice
versa. The total interaction cross-section is usually dom-
inated by the atomic processes of Compton effect and
pair creation. We consider conservatively any interacted
γ ray as lost. In reality, part of the Compton scatter-
ing goes forward under small angles and the γ rays that
have lost little energy can still induce photonuclear reac-
tions. The usable target thickness ranges from 20 g/cm2
for heavy elements to 40 g/cm2 for light elements, i.e.
in total only few mg target material are exposed to the
small area of the γ beam. With non-resonant reactions
of the order of 0.1 TBq activity can be produced per
day, corresponding to tens (for β− therapy isotopes) to
thousands (for imaging isotopes and therapy with alpha
emitters) of patient doses.
We consider metallic targets, although in praxi for
certain elements rather chemical compounds would be
used as targets. Usually oxides or other compounds with
light elements are used. These light elements have a
relatively low cross-section for gamma rays, hence the
specific activity achieved with compound targets is not
much lower compared to elemental targets.
The exact target geometry does not affect our esti-
mates. In principle a single compact target or a stack
of thin target foils could be used and would provide
similar production rates. In practice the latter solution
can stand far higher beam intensities. The foils could be
radiation-cooled in vacuum or helium-cooled, since he-
lium has a low Z and correspondingly low cross section
for interaction with gamma rays. Due to the low diver-
gence of the γ beam, the individual target foils can be
spaced wide apart, thus reducing the view factors be-
tween the foils to minimize mutual heating by radiation
absorption. For sufficiently thin foils most of the forward-
directed Compton and pair electrons and positrons can
leave the foil. Spacing the foils further apart reduces the
energy deposition from electrons of the previous foil,
which deposit their energy laterally (e.g. in a water-
cooled target chamber) spread over a wide area. The
trajectories of the electrons and positrons could even be
forced outward by applying transversal magnetic fields.
Also a stack of target foils with thin water-cooling chan-
nels in between can be considered since hydrogen and
oxygen have much lower interaction cross-sections with
gamma rays.
Alternatively to thin foils also a thin wire (e.g. 0.1
mm diameter) or several consecutive wires could be
placed along the γ beam direction. Here most electrons
and positrons that are emitted under angles different
from 0 degree will rapidly leave the target and not con-
tribute much to its heating. Even those that are initially
emitted forward will rapidly change direction by scatter-
ing and then leave the wire. In particular for less intense
γ beams such a solution may be simpler to realize than
a multi-foil stack.
All these heat dissipation techniques rely on the small
area, small divergence and small bandwidth of a γ beam.
They could not be applied for Bremsstrahlung spectra.
Thus, the extremely high flux densities of γ beams can
really be utilized without being seriously limited by the
required heat dissipation from the targets as is frequently
the case for charged-particle induced reactions or intense
Bremsstrahlung spectra.
Instead of producing a single product isotope at a
time, the target stack could also consist of different tar-
gets for simultaneous production of different isotopes.
This is possible when the different reactions require sim-
ilar γ energies. It may be particularly efficient when at
least one of the reactions is characterized by prominent
resonances, reducing the interaction length for resonant
γ rays. The “unused” γ rays within the bandwidth of
the γ beam may then be used downstream for other
reactions that are not resonant or have resonances at
different energies.
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Table 2 Longer-lived nuclear isomers produced in (γ, γ′) reactions. The relative population of the respective isomer in thermal
neutron capture on A-1 target isotopes is given as Iis/Igs where known experimentally. Experimental integrated cross sections
for population of the isomer by (γ, γ′) reactions at 4 MeV and 6 MeV were taken from [29,28]. The fraction of the maximum
specific activity produced in (γ, γ′) reactions Rγ , is put in relation to that obtained with (n,γ) reactions R(n,γ) at a thermal
neutron flux of 1014 n./(cm2 s) in the last column.
Iso- Isomer Iis/Igs Ground state σ · Γ Spec. act. Activity Rγ Spec. act. Rγ/R(n,γ)
tope Exc. Spin & T1/2 Spin & Nat. at at γ beam per day fraction high flux
energy parity parity abun. 4 MeV 6 MeV of max. reactor
keV d % eV·b eV·b GBq/mg GBq GBq/mg
87Sr 389 1/2− 0.12 3.5 9/2+ 7 3.9 8.7 10 110 2·10−5 0.57 18
115In 336 1/2− 0.19 9/2+ 95.7 18 67 58 603 3·10−4
117Sn 315 11/2− 13.8 0.04 1/2+ 7.68 3.2 8.8 7.5 0.6 0.0025 0.003 2400
119Sn 90 11/2− 293 0.02 1/2+ 8.59 0.002
123Te 248 11/2− 119 0.13 1/2+ 0.89 42 68 55 0.6 0.17 0.2 280
125Te 145 11/2− 57.4 0.17 1/2+ 7.07 70 0.08 0.48
129Xe 236 11/2− 8.9 0.10 1/2+ 26.4 0.2
131Xe 164 11/2− 11.8 0.10 3/2+ 21.2 0.2
135Ba 268 11/2− 1.2 0.08 3/2+ 6.59 13 60 44 33 1.5·10−3 0.045 1000
176Lu 123 1− 0.15 2.0 7− 2.59 140 350 2.0 1800 1.2·10−3 5.5 36
180Hf 1141 8− 0.23 0.01 0+ 35.1 0.14
193Ir 80 11/2− 10.5 3/2+ 62.7 10−5
195Pt 259 13/2+ 4.02 0.09 1/2− 33.8 30 140 72 17 0.012 0.019 3800
6.1 Isomers of stable isotopes via (γ, γ′)
reactions
Longer-lived nuclear isomers that decay by emission of
gamma rays and/or conversion electrons to the respec-
tive ground state are of interest for various applications
in nuclear medicine if they can be produced with high
specific activity. Table 2 shows a selection of such iso-
mers. The table shows in addition also other isomers that
have at present no application in nuclear medicine, but
are of interest e.g. for Mo¨ßbauer spectroscopy or even
gamma-ray lasers.
Most usual production methods, e.g. via (n,γ) reac-
tions, result in relatively low specific activity since the
dominant part of the production proceeds directly to
the nuclear ground state that has a nuclear spin closer
to that of the A-1 target isotope. However, the fact
that all these isomers are actually populated via ther-
mal neutron capture reactions on low-spinA-1 target iso-
topes proofs that pathways populating the high-spin iso-
mers from higher-lying, low-spin compound nucleus res-
onances levels of lower spins must exist. In Ref. [31] the
population of high-spin isomers relative to the ground
state was studied for resonances in (n,γ) reactions. An
energy dependence of the isomeric ratio was observed.
One may expect that this energy dependence would be-
come even more pronounced if the reactions were excited
with a primary beam of smaller bandwidth that popu-
lates more selectively states which decay mainly to the
isomeric level of interest.
Also photoexcitation (γ, γ′) experiments with Brems-
strahlung beams were performed on a series of stable
targets and showed strong population of isomeric levels
[27,29,30]. The observed energy dependence of the iso-
mer activation yields indicates that few gateway states
are responsible for populating efficiently the isomers.
It was recently demonstrated that Coulomb excita-
tion to states communicating by gamma transitions with
different isomeric states of a nucleus can be used to mod-
ify the initial isomeric composition [32]. We propose to
use a similar method, but using gamma rays with small
bandwidth directed onto the stable target nuclei. Com-
pared to Coulomb excitation or Bremsstrahlung spectra,
the excitation is far more selective and a much higher
conversion rate can be achieved due to the high gamma
ray flux density.
Moreover, photoexcitation with small bandwidth γ
rays allows moreover the selective excitation of individ-
ual levels or groups of levels that decay preferentially
to the nuclear isomer, thus enhancing the specific ac-
tivity of the isomer. Only in few cases the energies of
such (groups of) levels are already known. Note that
relatively low gamma ray energies may be sufficient for
such a pumping to isomeric states. In 125Te a 7/2+ state
at only 402 keV excitation energy can serve as gateway
state for pumping from the 1/2+ ground state to the
11/2− isomer at 145 keV [33].
We will estimate the achievable specific activity at
the example of 115In for which the required transition
energies, branching ratios and transition strengths are
already experimentally known, even if this isomer has
presently no application in nuclear medicine. The 9/2+
ground state of 115In can be excited by an E2 transition
from the ground state to the 5/2+ level at 1078.2 keV
that decays with 16% cumulative branching ratio to
the 1/2− isomer at 336 keV [33]. The gateway level
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at 1078 keV has a half-life of 0.99 ps, corresponding
to a total width Γ of 0.67 meV. The fractional width
to the ground state Γγ is 0.55 meV. while the decay
to the isomer has a width of Γd = 0.10 meV. Hence,
with the formula of equation 6 we obtain at the res-
onance energy Er = 1078 keV a peak cross-section
of σ(1078 keV) = 3400 b. The product of peak cross-
section times width is 2.3 eV·b. With a γ beam flux
density per eV of 1016γ/(cm2·s·eV) we obtain 193mIr
with a specific activity of 20 GBq/mg at saturation, i.e.
Rγ = 10
−4.
In many nuclei only a small fraction of excited levels
and transitions between them are experimentally known,
in particular for higher excitation energies. Also present
theoretical models do not allow to predict the exact po-
sition and decay modes of higher-excited levels. Only in
particular cases the population of high-spin isomers can
be explained with individual intermediate levels from ex-
periment and theory, see e.g. [27,30,34].
Experimental data on isomer population by (γ, γ′)
reactions had so far been obtained with Bremsstrahlung
spectra of large bandwidth. The integrated cross-
sections at γ energies of 4 and 6 MeV, respectively, are
of the order of 10 to 100 b·eV.
Many potential gateway states that could serve for
pumping nuclei from their ground state to isomeric lev-
els are expected to exist, but they still need to be iden-
tified by dedicated high resolution measurements from
excitation energies of few hundred keV up to close to
the particle separation energy. Thes measurements have
to be performed with the new γ beams for each of the
isotope for several thousand energy windows, in order
to determine the best excitation deexcitation path to
the isomer. Presently existing γ-ray beam facilities do
not provide sufficiently monochromatic γ-ray beams to
search for suitable resonance regions. A systematic in-
vestigation will require Compton backscattering facili-
ties such as MEGa-Ray or ELI-NP.
Selecting γ ray energies providing strong pumping
to the isomeric state will improve the achievable spe-
cific activity correspondingly. Even multiple excitations
of the path to the isomer are possible. Due to the miss-
ing energy match, no significant back-pumping from the
isomer to the ground state will occur.
Note that for populating isomeric levels in (γ, γ′) re-
actions they do not necessarily need to be excited close
to the neutron binding energy. To prevent competing
photonuclear reactions, it is actually more favorable to
select the lowest excited levels that decay populate with
sufficiently high yield the isomeric level.
Two examples of long-lived isomers with important
medical applications are discussed in the following:
1. 195mPt:
Platinum compounds such as cisplatin or carboplatin
are known to be cytotoxic and are frequently used
for chemotherapy of tumors. Labeling these com-
pounds with platinum radiotracers allows for in-
vivo pharmacokinetic studies and tumor imaging,
e.g. to monitor the patient-specific uptake and opti-
mize the dosing individually [35]. Failure to demon-
strate the tumor uptake of the chemotherapy agent
by nuclear imaging helps to exclude those “non-
responding” patients from unnecessary chemother-
apy treatment. 195mPt has 4 days half-life and emits
a 99 keV gamma ray that can be used for imaging by
SPECT or gamma cameras. 195mPt emits also low-
energy conversion and Auger electrons. Hence, when
used in higher activities, it could be suitable for a
combined chemo- and radionuclide therapy. Unfor-
tunately 195mPt is destroyed by (n,γ) reactions with
a very high cross section of 13000 barn. Therefore
the specific activity achievable by neutron capture
on 194Pt is seriously limited. Even at the HFIR re-
actor in Oak Ridge only 0.04 GBq/mg are obtained
[26] and too little activity is presently available for
clinical trials [36]. By (γ, γ′) reactions we expect to
obtain much higher specific activities, namely about
70 GBq/mg! About 20 GBq could be produced per
day, sufficient for several hundred patient-specific up-
take measurements or to launch first clinical trials for
radionuclide therapy with 195mPt. Moreover, even if
natural platinum or platinum compounds are irra-
diated, the radionuclidic purity of the product will
be excellent since no other long-lived radioisotopes
can be produced by activation with few MeV gamma
rays.
2. 117mSn:
Also 117mSn emits low-energy conversion and Auger
electrons, making it promising for radionuclide ther-
apy. In addition it emits a 159 keV gamma ray
for imaging. It has been shown that 117mSn can
be used for pain palliation in bone metastases of
various cancers. Due to its soft electron energy
spectrum it has less side effects on the bone mar-
row than other radioisotopes with more penetrat-
ing radiation [37]. Unfortunately the high-spin iso-
mer 117mSn is poorly produced in thermal neutron
capture on zero-spin 116Sn. With inelastic neutron
scattering 117Sn(nfast,n’γ) specific activities of 0.2
to 0.4 GBq/mg are obtained at high flux reactors
[26,38], but too little activity is presently available
[36]. Production via (γ, γ′) reactions with 6 MeV γ
beams allows boosting the specific activity at least
to 7 GBq/mg. About 0.6 GBq 117mSn are produced
per day, sufficient to start clinical trials.
These two isomers appear at present most interest-
ing for nuclear medicine applications. The specific activ-
ity and total production per day could be significantly
improved with still to be found better gateway states.
A detailed search for suitable gateway states at an up-
coming γ-beam facility with small bandwidth is urgently
needed.
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Table 3 Estimated production rates of radioisotopes produced in (γ,n), (γ,p) or (γ,2n) reactions. Experimental cross sections
were taken from [19], estimated cross sections are marked in italics. The fraction of the maximum specific activity produced in
(γ,x) reactions Rγ , is put in relation to that obtained with (n,γ) reactions R(n,γ) at a thermal neutron flux of 10
14 n/(cm2 s)
in the last column. ∗: For comparison we show the values for 99Mo produced by 98Mo(n,γ). However, usually 99Mo is produced
by fission with much better specific activity.
Product T1/2 Target Reaction Eγ σ Spec. act. Activity Rγ Spec. act. Rγ/R(n,γ)
isotope isotope γ beam per day fraction high flux reactor
d MeV b GBq/mg GBq of max. GBq/mg
47Ca 4.5 48Ca (γ,n) 19 0.09 1100 400 0.05 0.9 1200
64Cu 0.5 65Cu (γ,n) 17 0.09 830 1150 0.006 4 200
99Mo 2.8 100Mo (γ,n) 14 0.16 960 350 0.06 0.08∗ 12000
103Pd 17 104Pd (γ,n) 17 0.05 290 16 0.1 1.8 160
165Er 0.4 166Er (γ,n) 13 0.3 1100 1100 0.016 4.7 230
169Er 6.9 170Er (γ,n) 12 0.3 ≈ 800 130 ≈ 0.2 0.8 1000
186Re 3.7 187Re (γ,n) 15 0.6 ≈ 1400 320 ≈ 0.2 35 40
225Ra 14.8 226Ra (γ,n) 12 0.2 ≈ 300 30 ≈ 0.2
47Sc 3.4 48Ti (γ,p) 19 0.02 250 100 0.009
67Cu 2.6 68Zn (γ,p) 19 0.03 260 115 0.01
44Ti 60 y 46Ti (γ,2n) 27 0.01 ≈ 0.5 0.008 ≈ 0.1
224Ra 3.7 226Ra (γ,2n) 16 0.1 ≈ 50 10 ≈ 0.01
6.2 Radioisotopes via the (γ,n) reaction
When being excited well beyond the neutron binding
energy a nucleus loses readily a neutron. Competing re-
actions such as deexcitation by gamma ray emission are
far less probable.
1. 99Mo/99mTc:
The presently most used radioisotope for nuclear me-
dicine studies is 99mTc. Its 140 keV γ ray is ideal for
SPECT imaging. With a relatively short half-life of
6 h and the quasi-absence of beta particles the radia-
tion dose to the patient is low. 99mTc is conveniently
eluted in non-carrier-added quality from simple and
reliable 99Mo (T1/2 = 66 h) generators that can be
used for about one week. Various technetium com-
pounds have been developed for a multitude of nu-
clear medicine applications [1]. The combination of
these advantages explains why 99mTc is used in about
80% of all nuclear medicine studies. 28 millions ap-
plications employing 99mTc are performed per year.
Every week more than 80 kCi (3000 TBq) of 99Mo
have to be produced to load the 99Mo/99mTc gen-
erators that are shipped to the 99mTc users (mainly
hospitals) or to radiopharmacies. Until recently five
nuclear reactors were used to produce about 95%
of the world needs of 99Mo by neutron-induced fis-
sion of highly enriched 235U targets. Recently the two
reactors that used to produce the majority of the
99Mo supply had extended shutdowns, leading to a
serious 99Mo/99mTc supply crisis [39,40]. This trig-
gered large interest in alternative 99Mo/99mTc pro-
duction paths. One alternative production path uses
the 100Mo(γ,n) reaction. Usual Bremsstrahlung facil-
ities produce 99Mo with limited specific activity that
makes it more difficult to use the established gen-
erator technology (acid alumina columns). With γ
beams of high flux density, 99Mo could be produced
with much higher specific activity, allowing direct use
of existing generator technology. A facility providing
1015γ/s could produce via 100Mo(γ,n) reactions sev-
eral TBq per week. Thus, many such facilities would
be required to assure the worldwide 99Mo supply.
This example demonstrates that the new produc-
tion method by γ beams is not intended to com-
pete with large-scale production of established iso-
topes. The advantage of γ beams for radioisotope
production lies clearly in the very high specific ac-
tivity that can be achieved for radioisotopes or iso-
mers that are very promising for nuclear medicine,
but that are presently not available in the required
quality or quantity. Examples of such isotopes and
new clinical applications that may become available
with such radioisotopes produced by γ beams will be
discussed in the following.
2. 225Ra/225Ac:
Alpha emitters are very promising for therapeutic
applications, since the emitted alphas deposit their
energy very locally (typical range of one to few can-
cer cell diameters) with high linear energy transfer
(LET) and, hence, high probability for irreparable
double strand breaks. An alpha emitter coupled to
a cancer cell specific bioconjugate can be used for
targeted alpha therapy to treat disseminated cancer
types (leukemia), micro-metastases of various can-
cers or to destroy chemo- and radiation-resistant
cancer cells (e.g. glioblastoma). One promising al-
pha emitter is 225Ac (T1/2 = 10 days) that decays
by a series of four alpha decays and two beta de-
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Table 4 Radioisotopes of the neptunium chain produced in
the 226Ra(γ,n)225Ra reaction and subsequent decays.
Isotope α energy Mean β energy T1/2
(MeV) (MeV)
225Ra 0.1 15 d
225Ac 5.8 10 d
221Fr 6.3 4.9 min
217At 7.1 32 ms
213Bi 5.8 (2%) 0.4 (98%) 46 min
213Po 8.4 4.2 µs
209Pb 0.2 3.25 h
cays to 209Bi, see table 4. 225Ac (valence III) can
either be used directly for targeted alpha therapy, or
as generator for 213Bi that is used for targeted al-
pha therapy. Today 225Ac is produced by decay of
229Th→225Ra→225Ac and chemical separation. Un-
fortunately only small quantities (about 1 Ci=37
GBq per year) are available [41], which is far too lit-
tle for a large scale application. Alternatively, 226Ra
can be converted by (p,2n) reactions to 225Ac [42] or
by (γ,n) reactions to 225Ra that decays to 225Ac and
is subsequently chemically separated from the 226Ra
target [43]. The radioactive 226Ra targets are diffi-
cult to handle, when the activity of the target gets
important. Therefore a γ beam with high flux den-
sity is essential to minimize the target size and target
activity while maximizing the product activity. Thus
about 200 GBq 225Ac could be produced per week,
enough to treat hundreds of patients.
3. 169Er:
169Er decays with 9.4 days half-life by low-energy
beta emission (100 keV average beta energy). These
betas have a range of 100 to 200 µm in biological tis-
sue, corresponding to few cell diameters. The short
beta range makes this isotope very interesting for
targeted radiotherapy [44]. However, due to the low
168Er(nth, γ) cross section it cannot be produced with
high specific activity3 by neutron capture. Using in-
tense γ beams one can reach significantly higher spe-
cific activities via 170Er(γ,n) reactions.
4. 165Er:
165Er is one example for an isotope that decays
mainly by low-energy Auger electrons. Their range
is shorter than one cell diameter. Hence, these Auger
emitters have to enter the cell and approach the cell’s
nucleus to damage the DNA and destroy a cell. Cou-
pled to a bioconjugate that is selectively internalized
into cancer cells it can enhance the ratio for dose
equivalent delivered to the tumor cell with respect
to normal cells. This should result in an improved
3 Today 169Er with low specific activity is actually used for
radiation synovectomy to treat inflamed small joints, e.g. in
fingers [45].
tumor treatment with less side effects. R&D to iden-
tify suitable bioconjugates is under way [46].
5. 47Sc:
47Sc is a promising low-energy beta emitter for tar-
geted radiotherapy. Scandium is the lightest rare
earth element. Most established labeling procedures
for valence III metals (Y, Lu,. . . ) can be applied
directly for Sc. Its 159 keV gamma line allows
imaging of 47Sc distribution by SPECT or gamma
cameras. Alternatively the β+ emitting scandium
isotope 44Sc can be used for PET imaging as a
“matched pair”. Carrier-free 47Sc can be produced
by 50Ti(p,α) or 47Ti(nfast,p) reactions followed by
chemical separation. The alternative production via
46Ca(n,γ)47Ca→47Sc is uneconomic due to the ex-
tremely low natural abundance of 46Ca. At present
too little 47Sc is available [36], but with intense γ
beams the production via 48Ca(γ,n)47Ca→ 47Sc be-
comes competitive. After grow-in of 47Sc it is chem-
ically separated from the irradiated calcium, which,
after sufficient decay of 47Ca, can be reused to form
a new irradiation target.
6. 64Cu:
64Cu is a relatively long-lived β+ emitter (T1/2 =
12.7 h) with various applications in nuclear medicine
[47]. 64Cu-ATSM is a way to measure hypoxia of
tumors. Hypoxia is an important effect influencing
the resistance of tumor cells against chemo- or ra-
diation therapy. 64Cu can also act itself as thera-
peutic isotope due to its emission of β− (191 keV
mean energy) and low energy Auger electrons. To-
day 64Cu is mainly produced with small cyclotrons
by the 64Ni(p,n) reactions. Alternative production by
65Cu(γ,n) does not require the rare and expensive
64Ni targets and saves the chemical separation step.
7. 186Re:
186Re is a radioisotope suitable for bone pain pal-
liation, radiosynovectomy and targeted radionuclide
therapy. Rhenium is chemically very similar to its
homologue technetium, thus known compounds that
have been developed for imaging with 99mTc can
also be labeled with 186Re and used for therapy.
186Re is currently either produced by neutron cap-
ture on 185Re, resulting in limited specific activity, or
by 186W(p,n) reactions followed by chemical Re/W
separation. The latter guarantees excellent specific
activity at the expense of much reduced production
rates and a required chemical separation. Production
by 187Re(γ,n) would allow producing larger amounts
(2 TBq per week) of 186Re with high specific activ-
ity. Enriched 187Re targets should be used to min-
imize contamination of the product with long-lived
184,184mRe by 185Re(γ,n) reactions.
8. “Slightly neutron-deficient radioisotopes”:
“Slightly neutron-deficient isotopes” are decaying by
electron capture with emission of X-rays and low-
energy Auger electrons, partially also gamma rays
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and conversion electrons. The absence of beta emis-
sion and the presence of low-energy X-rays or elec-
trons is of advantage for a variety of applications such
as calibration sources, radionuclide therapy applica-
tions after internalization into cells, etc. All these
isotopes can be produced by neutron capture on the
stable (A-1) neighboring isotope. However, as shown
in Tab. 5, the latter is generally very rare in nature
(since only produced by unusual astrophysical pro-
cesses like the p-process) and correspondingly costly
when produced as isotopically enriched target mate-
rial. Using instead (γ,n) reactions to populate the
same isotopes allows using the much more abun-
dant, and hence cheaper, (A+1) neighboring isotope
as target. An example is 103Pd, a low-energy elec-
tron emitter. It can be used for targeted radionuclide
therapy (coupled to a suitable bioconjugate) or for
brachytherapy applications, where sources (“seeds”)
are inserted into a cancer (e.g. breast cancer [48,49])
for localized irradiation. However, the target 102Pd
for production by neutron capture is rare and expen-
sive. Production via 104Pd(γ,n) is more economic, if
sufficiently intense γ beams become available. The
same applies to other radioisotopes or isomers shown
in table 5 that have applications in nuclear medicine
or other fields.
6.3 Radioisotopes via the (γ,p) reaction
Even when excited beyond the proton binding energy,
a nucleus does not necessarily lose a proton. The lat-
ter is bound by the Coulomb barrier, leading to a sup-
pression of the proton loss channel. Only for excita-
tion well beyond the proton binding energy, the pro-
ton gains enough kinetic energy for tunneling efficiently
through the Coulomb barrier. However, such excitation
energies are usually also above the neutron binding en-
ergy or even the two-neutron binding energy. Hence neu-
tron emission competes with proton emission and the
cross sections for (γ,p) reactions may be one order of
magnitude lower than the competing channels (com-
pare Fig. 3). Thus, the achievable specific activity (spe-
cific activity with respect to the target mass) is limited
for (γ,p) reactions. However, the product isotope dif-
fers chemically from the target since it has one proton
less (Zproduct = Ztarget−1). After irradiation a chemical
separation of the product isotope from the target can
be performed, ultimately resulting in a high specific ac-
tivity that is only compromised by competing reactions
leading to other isotopes of the product element (such as
(γ,np), (γ,2n)EC/β+, etc.) or product burn-up by (γ,n).
1. 47Sc:
Besides the 48Ca(γ,n)47Ca→47Sc reaction, 47Sc can
also be produced via the 48Ti(γ,p) 47Sc reaction.
The established Sc/Ti separation schemes can be
Table 5 Comparison of target isotopes required for (n,γ)
and (γ,n) reactions respectively leading to the same radioiso-
topes or isomers. These have applications in nuclear medicine
or other fields. The last column shows the ratio of the natural
abundances of the A+1 and A-1 targets.
Product T1/2 (n,γ) nat. (γ,n) nat. [A+1]
isotope target abun. target abun. /
(d) (%) (%) [A-1]
47Ca 4.5 46Ca 0.004 48Ca 0.187 47
51Cr 27.7 50Cr 4.3 52Cr 84 20
55Fe 996 54Fe 5.8 56Fe 92 16
75Se 120 74Se 0.89 76Se 9.4 11
85Sr 65 84Sr 0.56 86Sr 9.9 18
97Ru 2.9 96Ru 5.5 98Ru 1.9 0.3
103Pd 17 102Pd 1.0 104Pd 11.1 11
109Cd 463 108Cd 0.89 110Cd 12.5 14
113Sn 115 112Sn 0.97 114Sn 0.66 0.7
121Te 16.8 120Te 0.09 122Te 2.6 29
127Xe 36 126Xe 0.09 128Xe 1.9 21
133mBa 1.6 132Ba 0.1 134Ba 2.4 24
139Ce 138 138Ce 0.25 140Ce 88 352
153Gd 239 152Gd 0.2 154Gd 2.2 11
159Dy 144 158Dy 0.095 160Dy 2.3 24
165Er 0.43 164Er 1.6 166Er 33.5 21
169Yb 32 168Yb 0.13 170Yb 3.04 23
175Hf 70 174Hf 0.16 176Hf 5.3 33
181W 121 180W 0.12 182W 26.5 221
191Pt 2.8 190Pt 0.014 192Pt 0.78 56
193mPt 4.3 192Pt 0.78 194Pt 33 42
employed for the chemical processing. Compared to
the 47Ti(n,p) way here the direct production of dis-
turbing long-lived 46Sc (via 46Ti(n,p) or 47Ti(γ,p),
respectively) can be limited more easily, since 48Ti
is the most abundant titanium isotope and can be
enriched more easily to high abundance. However,
the irradiation times have to be kept relatively short
to prevent excessive formation of 46Sc impurity by
47Sc(γ,n) reactions.
2. 67Cu:
67Cu is also a promising beta-emitter for targeted
radiotherapy. Alike 47Sc it has a sufficiently long
half-life for accumulation in the tumor cells when
bound to antibodies and its 185 keV gamma ray
allows imaging with SPECT or gamma cameras.
Together with the PET imaging isotopes 61Cu or
64Cu it forms a “matched pair”. The usual pro-
duction routes 68Zn(p,2p), 70Zn(p,α) or 64Ni(α,p)
are all characterized by low yields. The former re-
quires energetic protons (≫ 30 MeV from larger cy-
clotrons) and the latter two methods use expensive
enriched targets with low natural abundances. The
alternative production via 67Zn(n,p) requires a very
high flux of fast neutrons, which is only available in
few reactors. At present clinical trials with 67Cu are
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Table 6 Therapy radioisotopes that can be produced in
(γ,p) reactions
isotope mean beta T1/2 target isotope
energy natural abundance
(keV) (days) (%)
47Sc 162 3.35 48Ti (73.7%)
67Cu 141 2.58 68Zn (18.7%)
131I 182 8.03 132Xe (26.9%)
161Tb 154 6.91 162Dy (25.5%)
177Lu 134 6.65 178Hf (27.3%)
hindered by insufficient supply [36]. Production via
68Zn(γ,p) reactions induced by intense γ beams pro-
vides higher activities and uses more abundant, and,
hence cheaper 68Zn targets. The established Cu/Zn
separation schemes can be employed for the required
chemical processing.
3. Isotopes with higher Z:
In principle also heavier β− emitters used for ra-
dionuclide therapy such as 131I, 161Tb or 177Lu could
be produced by (γ,p) reactions (on 132Xe, 162Dy or
178Hf targets respectively). However, for higher Z the
increasing Coulomb barrier leads to small production
cross sections. Production in high flux reactors by
neutron-induced fission (for 131I) or by neutron cap-
ture on the (A − 1,Z − 1) target (130Te, 160Gd or
176Yb respectively), followed by decay and chemical
separation leads to products with excellent specific
activity and is more economic.
6.4 Radioisotopes via the (γ,2n) reaction
1. 44Sc:
44Sc is a promising metallic PET tracer that emits a
1157 keV gamma-ray quasi-simultaneously with the
positron. With a suitable detection system (Comp-
ton telescope plus PET camera), a triple coincidence
(gamma rays of 511 keV, 511 keV, and 1157 keV)
can be detected [50]. Hence, for each triple-event the
point of emission is derived instead of the usual line-
of-response, leading to improved position resolution
at reduced dose to the patient. Moreover 44Sc forms
a “matched pair” with 47Sc, a therapy isotope dis-
cussed above. 44Sc can be obtained from 44Ti/44Sc
generators where the parent isotope 44Ti is very long-
lived (T1/2 = 60 years). Despite the very favorable
properties of 44Sc, this isotope is not yet used in clin-
ical routine, since the generator isotope 44Ti is dif-
ficult to produce and therefore prohibitively expen-
sive. The current cost for 200 MBq of 44Ti, the typ-
ical activity for one 44Ti/44Sc generator for human
use, is about 2 million EUR! Exposing enriched 46Ti
(natural abundance 8%) to an intense γ beam allows
producing 44Ti by (γ,2n) reactions. It will take about
three weeks of irradiation in a mid-sized γ beam facil-
ity to generate 200 MBq of 44Ti, but such a generator
(or several subsequent generators that use the same
recycled 44Ti activity) can be eluted several times a
day and serve for tens of years.
2. 224Ra/212Pb/212Bi:
Via 226Ra(γ,2n) reactions the isotope 224Ra (T1/2
= 3.66 d) from the thorium chain can be obtained,
where the noble gas 220Rn isotope can be extracted
easily. The α emitter 212Bi (T1/2 = 60 min) in this
decay chain or its mother isotope 212Pb are also con-
sidered for targeted alpha therapy, e.g. for malignant
melanoma metastases [51,52].
6.5 Other photonuclear reaction channels
In (γ,2p) reactions even two protons must overcome the
Coulomb barrier, making this reaction channel even less
likely than the (γ,p) reaction. Measured cross-sections
for (γ,2p) reactions exist for 63Cu(γ,2p)61Co [53]. They
range from few µ-barn at 30 MeV to 14 µbarn at 60 MeV.
Also for (γ,α) reactions the higher Coulomb barrier leads
to small cross-sections in the microbarn range. Usually
other production reactions provide better yields, making
these types of photonuclear reaction less competitive.
Photo-fission of uranium or thorium targets allows
production of 99Mo and other isotopes with highest spe-
cific activity. However, the here proposed γ beams with
high flux density are not suitable since they lead to an
excessive target heating. In each fission about 200 MeV
are released, the dominant part as kinetic energy of the
fission fragments that will stop within few µm range.
This would lead to power densities of several hundred
kW per cm3, impossible to cool from the targets.
7 Photonuclear Activation for Brachytherapy
Applications
Certain nuclear medicine applications use the radioiso-
topes “directly”, i.e. not necessarily coupled to a bio-
molecule.
There are various applications for micro- or nanopar-
ticles that are doped with radioisotopes. They can be
used for radioembolization of ,e.g., liver cancer or liver
metastases [54]. The radioactive microparticles are di-
rectly injected into the arteries supplying the tumor,
then irradiate the latter with their medium-range ra-
diation (beta particles, low-energy X-rays or gamma
rays). Similarly, nanoparticles are considered for target-
ing tumors. The radioisotopes can be introduced into the
micro- or nanoparticles in various ways:
1. The radioisotopes can be added to the raw mate-
rials used in the chemical synthesis of the micro-
or nanoparticles. However, this makes the process-
ing much more involved, since radioactive material
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has to be handled and the respective radiological and
contamination issues have to be addressed in the pro-
duction facility.
2. The radioisotopes can be implanted in form of a ra-
dioactive ion beam into the ready-made micro- or
nanoparticles [55]. This method is quite universal,
allowing to dope even with radioisotopes of elements
that are usually not soluble in or chemically compat-
ible with the matrix. However, the radioactive iso-
topes first need to be brought into a radioactive ion
beam which may be more involved depending on the
chemical element.
3. A stable precursor of the radioisotope can be intro-
duced prior to the chemical synthesis of the micro- or
nanoparticles or ion-implanted after synthesis. Then
the precursor is transmuted in a nuclear reaction
into the desired radioisotope. However, the micro-
or nanoparticles may be sensitive to radiation dam-
age. Hence activation ,e.g., in a nuclear reactor could
damage them such that they are no longer usable
in in-vivo applications. For neutron activation it has
been shown that resonance capture of epithermal
neutrons (“adiabatic resonance crossing” method)
can be of advantage to overcome this problem [56].
Here we propose a complementary method of activa-
tion by photonuclear reactions. For the isotopes listed
in table 5 the general advantages discussed above ap-
ply. In addition the high cross section ratio of “use-
ful” photonuclear reactions versus “disturbing” reac-
tions causing radiation damage allows obtaining rel-
atively high activities.
Radioisotopes can also be bound in larger solid ma-
trices that are then mechanically (surgically) introduced
into the body or brought close to it to irradiate tumors
or benign diseases. Such a so-called brachytherapy is to-
day routinely used to treat prostate cancer by perma-
nently introduced seeds containing radioactive 125I [57].
It is also useful to prevent in-stent restenosis by intravas-
cular brachytherapy using radioactive stents [58], pre-
vent closure of the pressure relief channel in glaucoma
filtering surgery by radioactive implants [59] or perform
other anti-inflammatory or anti-proliferative treatments.
Photonuclear reactions could simplify the production of
the respective stents or seeds. Instead of introducing the
radioactive isotopes in the production process or ion-
implanting it afterwards, it will be possible to produce
the stents or seeds in their final form and then activate a
previously included stable precursor isotope by photonu-
clear reactions. Selective photonuclear reactions assure
to keep the radiation damage of the matrix low and avoid
an unwanted production of disturbing radioisotopes by
activation of the matrix.
8 Advantages of the Proposed Photonuclear
Reactions over Existing Technologies
The intense brilliant γ beam will allow to produce ra-
dioisotopes with rather high specific activity. Advantages
of γ ray beams with small opening angle are:
– The produced radioisotopes are concentrated in a
small target volume, hence resulting in much higher
specific activity than usual.
– Much less of the (often costly) target material is re-
quired.
– Radioactive targets are more efficiently converted
into the required product isotopes, hence more com-
pact and less active targets can be employed, result-
ing in less activity to be handled and less dose rate.
Additional advantages when using the low band-
width γ ray beams are:
– The higher cross section for monochromatic beams
leads to a short interaction length (cm or less). This
leads to an additional reduction of the required target
mass, hence further reducing the target costs and
increasing the specific activity.
– Compared to Bremsstrahlung beams a much reduced
γ ray heating per useful reaction rate occurs since
the γ rays in the useful energy range are not ac-
companied by an intense low-energy tail. Moreover
the usual equilibrium between γ-rays and electrons
(which are responsible for the actual heating) will
build up only for very thick targets.
– Much reduced radiation damage due to quasi-mono-
chromatic beams will make it possible to first
dope and then activate materials (e.g. organic,
nanoscale,. . . ) that would not withstand irradiation
in a nuclear reactor or a bremsstrahlung γ ray spec-
trum.
– Isotopic enrichment may not necessarily be needed,
when for a given γ energy the wanted cross section
is much higher than for other isotopes. In particu-
lar, the fine structure of the Pygmy dipole resonance
(PDR), probably similar to the giant dipole reso-
nance (GDR), could be exploited.
– Also less stringent requirements exist concerning iso-
topic enrichment or chemical impurities of the target
materials if the γ ray energy is chosen such that the
maximum cross sections of the wanted production
channels corresponds to minima in the cross section
of activation of impurities.
– Selective production reduces the overall activity level
of the irradiated target and reduces the challenge to
the chemical post-processing.
Moreover, there are practical advantages of photonu-
clear reactions compared to charged-particle induced re-
actions: Radioactive targets like 226Ra or targets that
risk to react heavily in contact with cooling water (e.g.
alkali metals) can be safely encapsulated into relatively
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thick metal walls, since gamma rays penetrate easily and
cause less heating of the walls than charged particles do.
A further optional increase of the specific activity is
possible by:
– Enriched target isotopes may be used.
– A thin target or a stack of thin target foils inter-
leaved with a different solid, liquid or gas that acts
as catcher of recoil ions. Extraction and separation of
the recoiled product isotopes can be performed with
the usual radiochemical methods.
– If the produced radioisotope belongs to a different
chemical element than the target (e.g. for (γ,p) re-
actions), a usual radiochemical post-processing (e.g.
ion exchange chromatography, liquid-liquid extrac-
tion, etc.) can be employed to separate the product
element from remainders of the target element and
thus increase the specific activity of the product.
– A product isotope that decays to a radioactive
daughter isotope with medical applications allows
producing a generator.
Conclusion and Outlook
Laser beams revolutionized atomic physics and its appli-
cations, not only due to their coherence, but often just
due to their high photon flux density or their high spec-
tral photon flux density. Similarly gamma beams open
many new possibilities in nuclear physics and its applica-
tions. Alike in atomic physics such beams can be used to
pump a good fraction of the nuclear ground state popula-
tion via excited levels into an isomeric state. While (far)
ultraviolet laser beams can efficiently photoionize atoms
by exciting a valence electron to an unbound state, ener-
getic gamma beams can efficiently excite a nucleon (neu-
tron or proton) into an unbound state leading to photo-
dissociation and creation of a new isotope. When these
reactions are resonantly enhanced the monochromaticity
of laser or gamma beams respectively is decisive.
Using the new γ beam facilities we can use compact
targets, which are exposed to the gamma radiation and
undergo photonuclear reactions such as (γ, γ′), (γ,n),
(γ,p), etc. to form radioisotopes. After a suitable irra-
diation time, a radioisotope with high specific activity is
produced. After the usual radiochemical and radiophar-
maceutical steps (such as optionally dissolving of the
target, optionally chemical purification, labeling, quality
control,. . . ) a radiopharmaceutical product is created for
use in diagnostic or therapeutic nuclear medicine proce-
dures. The produced radioisotope may be used directly
for nuclear medicine applications.
The investment and running costs of the proposed
γ beam facilities are of the order of 40 MEUR and few
MEUR/year. This is cheaper than a high-flux reactor ,
but more expensive than compact cyclotrons that pro-
vide charged particle beams with 10 to 20 MeV energy
suitable for production of PET tracers. World-wide more
than 600 such cyclotrons exist, often based at hospitals
or close-by. They provide regularly the short-lived PET
isotopes 18F (T1/2 = 110 min),
11C (20 min), 13N (10
min) and 15O (2 min) for molecular imaging applica-
tions. Although it would be possible to produce also such
isotopes by photonuclear reactions (e.g. 20Ne(γ,np)18F),
a more complex Compton backscattering facility would
be clearly an overkill for such applications.
The selection of radioisotopes presently used in nu-
clear medicine routine applications is actually dictated
by the radioisotope’s availability at reasonable costs.
This selection is not necessarily optimized for all clin-
ical applications with respect to optimum nuclear (half-
life, decay radiation) and chemical properties (labeling
efficiency, in-vivo stability of compounds, etc.). Other
radioisotopes might be advantageous for the patient but
are presently not available. The main advantage of the
γ beam facility is the new and rather unique access to
radioisotopes or isomers with high specific activity that
can complement and extend the choice of radioisotopes
for nuclear medicine applications.
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